We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.18 | -0.36% | 49.28 | 49.47 | 49.50 | 796 | 11:19:16 |
From May 2019 to May 2024
By William Horobin
PARIS--France's Sanofi SA (SAN.FR) and U.S. biopharma company Regeneron Pharmaceuticals Inc. (REGN) said Tuesday that Japanese authorities have authorized the drug companies' cholesterol treatment Praluent.
Praluent has already been approved in the U.S., the European Union, Canada and Mexico. In Japan, ministry of health, labor and welfare granted marketing and manufacturing authorization for Praluent for the treatment of patients with hypercholesterolemia and familial hypercholesterolemia in whom treatment with statins isn't sufficient.
"Hypercholesterolemia is a significant concern in Japan," said Jay Edelberg, Head of Cardiovascular Development at Sanofi.
-Write to William Horobin at william.horobin@wsj.com
(END) Dow Jones Newswires
July 05, 2016 02:03 ET (06:03 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
